ALKERAN

LOE Approaching

melphalan

NDAORALTABLETPriority Review
Approved
Jan 1964
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

CLINICAL PHARMACOLOGY: Melphalan is an alkylating agent of the bischloroethylamine type. As a result, its cytotoxicity appears to be related to the extent of its interstrand cross-linking with DNA, probably by binding at the Nposition of guanine. Like other bifunctional alkylating agents, it is…

Indications (1)

Clinical Trials (5)

NCT06875128Phase 2Recruiting

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

Started Jan 2026
90 enrolled
Metastatic Breast Cancer in the Liver
NCT07276386Phase 2Recruiting

Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma

Started Dec 2025
18 enrolled
Metastatic Uveal Melanoma
NCT06607458Phase 2Recruiting

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease

Started Aug 2025
90 enrolled
Refractory Metastatic Colorectal Cancer
NCT06679829Phase 2Recruiting

A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant

Started Nov 2024
215 enrolled
Multiple Myeloma
NCT05438394Phase 1Unknown

Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MM

Started Oct 2022